Genetics of common forms of heart failure

Current Opinion in Cardiology

Volumn 26, Issue 3, 2011, Pages 204-208

  Dorn II, Gerald W ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

candidate gene; genome wide association study; heart failure; polymorphisms

Indexed keywords

ALPHA 2C ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR; BUCINDOLOL; CARVEDILOL; G PROTEIN RECEPTOR KINASE 5; GUANINE NUCLEOTIDE BINDING PROTEIN; METOPROLOL; UNCLASSIFIED DRUG;

ARTICLE; CARDIOVASCULAR RISK; GENE DELETION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENETICS; GENOTYPE; HEART FAILURE; HEREDITY; HUMAN; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GTP-BINDING PROTEIN REGULATORS; HEART FAILURE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC; RECEPTORS, ADRENERGIC, ALPHA-2; RISK FACTORS;

EID: 79955052165     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e328345d336     Document Type: Article

References (35)

1. Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008; 101:1016-1022.
2. Lloyd-Jones D, Adams RJ, Brown TM, et al. Executive summary: heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 2010; 121:948-954.
3. Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med 2006; 355: 138-147. (Pubitemid 44050395)
4. Mialet PJ, Rathz DA, Petrashevskaya NN, et al. Beta 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 2003; 9:1300-1305. (Pubitemid 37279854)
5. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits betaadrenergic receptor signaling is protective in heart failure. Nat Med 2008; 14:510-517. (Pubitemid 351655214)
6. Larson MG, Atwood LD, Benjamin EJ, et al. Framingham Heart Study 100K project: genome-wide associations for cardiovascular disease outcomes. BMC Med Genet 2007; 8 (Suppl 1):S5.
7. Smith NL, Felix JF, Morrison AC, et al. Association of genome-wide variation with the risk of incident heart failure in adults of European and African ancestry: a prospective meta-analysis from the cohorts for heart and aging research in genomic epidemiology (CHARGE) consortium. Circ Cardiovasc Genet 2010; 3:256-266.
8. Morrison AC, Felix JF, Cupples LA, et al. Genomic variation associated with mortality among adults of European and African ancestry with heart failure: the cohorts for heart and aging research in genomic epidemiology consortium. Circ Cardiovasc Genet 2010; 3:248-255.
9. Dorn GW 2nd. Adrenergic signaling polymorphisms and their impact on cardiovascular disease. Physiol Rev 2010; 90:1013-1062.
10. Packer M. The neurohormonal hypothesis: a theory to explain themechanism of disease progression in heart failure. J Am Coll Cardiol 1992; 20:248-254.
11. Mason DA, Moore JD, Green SA, et al. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999; 274:12670-12674.
12. Joseph SS, Lynham JA, Grace AA, et al. Markedly reduced effects of - isoprenaline but not of -CGP12177 and unchanged affinity of betablockers at Gly389-beta1-adrenoceptors compared to Arg389-beta1-adrenoceptors. Br J Pharmacol 2004; 142:51-56. (Pubitemid 38698193)
13. Wagoner LE, Craft LL, Zengel P, et al. Polymorphisms of the beta1-adrenergic receptor predict exercise capacity in heart failure. Am Heart J 2002; 144:840-846. (Pubitemid 35335176)
14. Sandilands AJ, Parameshwar J, Large S, et al. Confirmation of a role for the 389R
15. Cresci S, Kelly RJ, Cappola TP, et al. Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol 2009; 54:432-444.
16. Baudhuin LM, Miller WL, Train L, et al. Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure. Am J Cardiol 2010; 106:402-408.
17. Metra M, Covolo L, Pezzali N, et al. Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovasc Drugs Ther 2010; 24:49-60.
18. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and betablocker response in human heart failure. Proc Natl Acad Sci U S A 2006; 103:11288-11293. (Pubitemid 44156511)
19. Chemello D, Rohde LE, Santos KG, et al. Genetic polymorphisms of the adrenergic system and implantable cardioverter-defibrillator therapies in patients with heart failure. Europace 2010; 12:686-691.
20. Fauchier L, Pierre B, de Labriolle A, et al. Comparison of the beneficial effect of beta-blockers on mortality in patients with ischaemic or nonischaemic systolic heart failure: a meta-analysis of randomised controlled trials. Eur J Heart Fail 2007; 9:1136-1139. (Pubitemid 47633317)
21. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002; 347:1135-1142.
22. Savva J, Maqbool A, White HL, et al. Polymorphisms of adrenoceptors are not associated with an increased risk of adverse event in heart failure: aMERIT-HF substudy. J Card Fail 2009; 15:435-441.
23. Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail 2010; 3:21-28.
24. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001; 53:1-24. (Pubitemid 32173106)
25. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem 1998; 67:653-692. (Pubitemid 28411141)
26. Wang WC, Mihlbachler KA, Bleecker ER, et al. A polymorphism of G-protein coupled receptor kinase5 alters agonist-promoted desensitization of beta2- adrenergic receptors. Pharmacogenet Genomics 2008; 18:729-732.
27. Spinelli L, Trimarco V, Di MS, et al. L41Q polymorphism of the G protein coupled receptor kinase 5 is associated with left ventricular apical ballooning syndrome. Eur J Heart Fail 2010; 12:13-16.
28. Lyon AR, Rees PS, Prasad S, et al. Stress (Takotsubo) cardiomyopathy: a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 2008; 5:22-29.
29. Wittstein IS, Thiemann DR, Lima JA, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med 2005; 352:539-548. (Pubitemid 40204667)
30. Bodmer W, Bonilla C. Common and rare variants in multifactorial susceptibility to common diseases. Nat Genet 2008; 40:695-701. (Pubitemid 351748875)
31. Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease. J Clin Invest 2008; 118:1590-1605. (Pubitemid 351632361)
32. Keating BJ, Tischfield S, Murray SS, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 2008; 3:e3583.
33. Cappola TP, Li M, He J, et al. Common variants in HSPB7 and FRMD4B associated with advanced heart failure. Circ Cardiovasc Genet 2010; 3:147-154.
34. Stark K, Esslinger UB, Reinhard W, et al. Genetic association study identifies HSPB7 as a risk gene for idiopathic dilated cardiomyopathy. PLoS Genet 2010; 6:e1001167.
35. Matkovich SJ, Van Booven DJ, Hindes A, et al. Cardiac signaling genes exhibit unexpected sequence diversity in sporadic cardiomyopathy, revealing HSPB7 polymorphisms associated with disease. J Clin Invest 2010; 120:280-289.